Interpret the estimand framework from a causal inference perspective

Jinghong Zeng

Jiangsu Hengrui Pharmaceuticals Co. Ltd., China jinghong.zeng.jz9@hengrui.com

Abstract

The estimand framework proposed by ICH in 2017 has brought fundamental changes in the pharmaceutical industry. It clearly describes how a treatment effect in a clinical question should be precisely defined and estimated, through attributes including treatments, endpoints and intercurrent events. However, ideas around the estimand framework are commonly in text, and different interpretations on this framework may exist. This article aims to interpret the estimand framework through its underlying theories, the causal inference framework based on potential outcomes. The statistical origin and formula of an estimand is given through the causal inference framework, with all attributes translated into statistical terms. How five strategies proposed by ICH to analyze intercurrent events are incorporated in the statistical formula of an estimand is described, and a new strategy to analyze intercurrent events is also suggested. The roles of target populations and analysis sets in the estimand framework are compared and discussed based on the statistical formula of an estimand. This article recommends continuing study of causal inference theories behind the estimand framework and improving the estimand framework with greater methodological comprehensibility and availability.

Keywords: estimand, causal inference, ICH E9

1 Introduction

The estimand framework was drafted in 2017 by ICH in Efficacy Guideline E9(R1) as addendum to Efficacy Guideline E9 and later published in 2019 [2,3]. It has gained increasing attention in the pharmaceutical industry. Many clinical trials have used the estimand framework to develop new drugs for both oncology and non-oncology diseases [4], and professional working groups such as the Oncology Estimand Working Group (https://oncoestimand.github.io/oncowg_webpage/docs/) have been initiated to study how the estimand framework should be incorporated in pharmaceutical practices.

The estimand framework aims to clearly define a clinical question. This means to clearly define a treatment effect in this clinical question. The estimand framework introduces and compares estimands, estimators and estimates with regard to statistical roles in estimation of treatment effects. An estimand is a precise definition of a treatment effect in a clinical question, an estimator is a statistical method that estimates this estimand, and an estimate is a result from this estimator [3]. Five attributes are proposed for an estimand. They are treatments, endpoints, a target population, intercurrent events, population-level summary [3]. Treatments are medical interventions that patients would take in clinical trials. Endpoints are outcomes used to assess efficacy and safety of treatments. A target population is a group of patients with medical conditions of clinical interest. Intercurrent events are events that happen after treatment initiation and affect the definition of a treatment effect. Population-level summary is an approach to estimate the treatment effect in a target population.

Intercurrent events are frequent in practice but conceptually novel. E9(R1) listed many examples for intercurrent events, such as use of concomitant therapies, treatment switching and death before endpoint measurement. To suit different study objectives, five strategies have been proposed to reduce bias from intercurrent events. They are the treatment policy strategy, the hypothetical strategy, the composite variable strategy, the while on treatment strategy, the principal stratum strategy [3].

The estimand framework is still a relatively new concept, where different interpretations may exist. Any contribution to further clarification of the estimand framework would be beneficial for clinical development. The original ideas in the estimand framework are mainly conveyed through text, but a statistical description of the estimand framework may be more intuitive, precise and holistic. The core of the estimand framework is treatment effects, and attributes of an estimand are developed to define a treatment effect. It would be helpful to understand a treatment effect through a statistical causal inference framework and see how these attributes and strategies are related to underlying theories.

2 The causal inference framework for estimands

A causal inference framework is based on the potential outcome framework [1,5]. Suppose there is an ideal two-arm randomized controlled clinical trial, with full compliance to treatment and no intercurrent events. This trial has a sample size of N, a binary treatment X, a continuous endpoint Y, a randomization scheme R and some confounders C that affect both X and Y. X, Y, R are random vectors of length N, and C is a random matrix of row dimension N. X_i, Y_i, R_i C_i represent random variables or vectors for a participant *i*, where $i \in \{1, 2, 3, \dots, N\}$. $R_i = 0$ means that the participant is assigned to the control arm and $R_i = 1$ means that the participant is assigned to the treatment arm. $X_i(R_i = 0) = 0$ means that the participant would take the control treatment if assigned to the control arm and $X_i(R_i = 1) = 1$ means that the participant would take the experimental treatment that is of primary clinical interest if assigned to the treatment arm. $Y_i(X_i(R_i = 0) = 0)$ would be the endpoint if the participant took the control treatment and $Y_i(X_i(R_i=1)=1)$ would be the endpoint if the participant took the experimental treatment. R_i , X_i and Y_i are potential outcomes. They are not real because we hypothesize what would happen if the participant took the control treatment or instead took the experimental treatment. Figure 1 is a causal directed acyclic graph that shows the causal relationships between X, Y, R, C. R affects Y only through X.

A clinical question is to estimate the overall treatment effect of taking the experimental treatment versus taking the control treatment on the endpoint over all participants. For the participant i, if he had $X_i(R_i = 0) = 0$ then he would have $Y_i(X_i(R_i = 0) = 0)$, and if had $X_i(R_i = 1) = 1$ then he would have $Y_i(X_i(R_i = 1) = 1)$. Hence, for this participant, an individual treatment effect is $Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0)$. This individual treatment effect controls confounders on the endpoint within the same participant and means how the endpoint would



Figure 1: Causal directed acyclic graph for X, Y, R, C.

change when only the treatment condition changes. There are N individual treatment effects. They can be assumed to be equal or unequal. Generally, we are interested in an average treatment effect (ATE) among all participants. The ATE is an average of all individual treatment effects and can be described as $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C))$. And the estimand in this clinical question is the ATE. If there is no confounder, the ATE would become $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0)))$. Without adjusting for existing confounding effects, the ATE estimation may be biased.

Further, $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C) = E(Y_i(X_i(R_i = 1) = 1) | C) - E(Y_i(X_i(R_i = 0) = 0) | C)$. This also means that the estimand is the difference between the ATE of taking the experimental treatment among all participants and the ATE of taking the control treatment among all participants. The problem is that, in real world, each participant only takes one kind of treatment, and only one of the two hypothetical situations with regard to two arms can happen. In this ideal trial, the observed randomized assignment R_i^o is either 0 and 1, the observed treatment X_i^o is either $X_i(R_i = 0)$ or $X_i(R_i = 1)$, and the observed outcome $Y_i^o(X_i^o)$ is either $Y_i(X_i(R_i = 0))$ or $Y_i(X_i(R_i = 1))$. Hence, the relationship between potential outcomes and observed variables can be described as

$$X_{i}^{o} = X_{i}(R_{i} = R_{i}^{o}), Y_{i}^{o} = Y_{i}(X_{i}(R_{i} = R_{i}^{o})).$$

What we can estimate from the actual trial data is the difference between the ATE from participants who take the experimental treatment in the treatment arm and the ATE from participants who take the control treatment in the control arm, that is, $E(Y^o \mid X^o = 1, R^o = 1, C) - E(Y^o \mid X^o = 0, R^o = 0, C)$. With certain assumptions including the stable unit treatment value assumption, the randomization assumption and the exclusion restriction assumption, it can proved that $E(Y^o \mid X^o = 1, R^o = 1, C) - E(Y^o \mid X^o = 0, R^o = 0, C) = E(Y^o \mid X^o = 1, C) - E(Y^o \mid X^o = 0, R^o = 0, C) = E(Y^o \mid X^o = 1, C) - E(Y^o \mid X^o = 0, R^o = 0, C) = E(Y^o \mid X^o = 1, C) - E(Y^o \mid X^o = 0, C) = E(Y(X_i(R_i = 1) = 1) \mid C) - E(Y(X_i(R_i = 0) = 0) \mid C))$. Without these assumptions, this equality chain will not hold.

Suppose we choose a causal linear model to estimate the estimand. The linear model is

$$Y^{o} = \beta_{0} + \beta_{1}X^{o} + \beta_{2}C + \varepsilon, E(\varepsilon) = 0, Var(\varepsilon) = \sigma^{2},$$

where $E(Y^o \mid X^o, C) = \beta_0 + \beta_1 X^o + \beta_2 C$. Then, $E(Y^o \mid X^o = 0, C) = \beta_0 + \beta_2 C$ and $E(Y^o \mid X^o = 1, C) = \beta_0 + \beta_1 + \beta_2 C$, which implies that $E(Y^o \mid X^o = 1, C) - E(Y^o \mid X^o = 0, C) = \beta_1$. Hence, β_1 equals to the ATE and thus is an estimator to the estimand from this linear model. After the linear model is built with the actual trial data, an estimate $\hat{\beta}_1$ on β_1 would be obtained, and $\hat{\beta}_1$ would be an estimate to the estimand.

The statistical formula of the estimand as $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C)$ has already contained five attributes proposed in the estimand framework. The attribute of treatments is represented by X. The attribute of endpoints is represented by Y. The attribute of populationlevel summary is represented by the difference between two ATEs. The attribute of intercurrent events is not necessary here since no intercurrent events are assumed. The attribute of a target population is implicitly stated as the trial population and can be made explicit in the definition of the estimand. We can introduce a selection variable S that indicates how the target population is selected from the general public and update the estimand to $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C, S)$.

The causal inference framework is not restricted to the above situation. It is applicable to multivalued treatments, discrete outcomes and Bayesian methods. It is also the underlying theory that applies to any effort of estimating treatment effects. We may have used it, even if the causal inference framework does not appear explicitly in inference, because potential outcomes have been transformed to observed variables in statistical models and we only see observed variables. Causal inference is a mature, continuing research area in Statistics. Methods may be available for difficult practical problems. Hence, it would be recommended that we try to interpret the estimand from a causal inference perspective based on our study objectives, and understand or choose relevant methods to estimate estimands.

3 Causal inference with intercurrent events

The attribute of intercurrent events can also be incorporated in the statistical formula of an estimand. Following the trial example in the last section, suppose now the trial has intercurrent events shown in figure 2. Also suppose the endpoint is not related to death and the second assessment on the endpoint is used for primary analysis. We use these intercurrent events to discuss the statistical formula of an estimand in different strategies.

3.1 The treatment policy strategy

The treatment policy strategy is to include intercurrent events in the treatment definition. In case (1), when concomitant therapies are used, the endpoint may also be affected by concomitant therapies in addition to the control and experimental treatments. Hence, we cannot estimate the ATE of the experimental treatment versus the control treatment on the endpoint without adjusting for concomitant therapies. Through the treatment policy strategy, we re-define X as the control or experimental treatment plus any concomitant therapy. Then we can use all participants from case (1) in data analysis. The estimand formula is still $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C)$, but now the estimand has been changed into the ATE of the experimental treatment plus any concomitant therapy.

This strategy does not estimate the pure effect of the experimental treatment. When concomitant therapies are common for use with the experimental treatment in real world, this strategy would be appropriate.



Figure 2: Different intercurrent events. Case (1): Participants use concomitant therapies after treatment initiation and continue study till the end. The second assessment on the endpoint is available. Case (2): Participants die by the second assessment. The second assessment on the endpoint is not available. Case (3): Participants die between two assessments. The second assessment on the endpoint is not available but the first assessment on the endpoint is available. Case (4): Participants discontinue treatment after treatment initiation due to treatment toxicity and withdraw from study. No endpoint assessment is available.

3.2 The hypothetical strategy

The hypothetical strategy is to hypothesize non-existence of intercurrent events and make relevant endpoints missing. Suitable statistical methods should be used to impute missing endpoints.

In case (1), if concomitant therapies are prohibited by the protocol, we cannot include concomitant therapies in the treatment definition and the endpoint assessments after prohibited therapies are used are not appropriate for analysis. Through the hypothetical strategy, we make the second assessment on the endpoint after prohibited therapies are used missing and impute missing endpoint assessments as if there were only the control and experimental treatments. In case (2), the second assessment on the endpoint is naturally missing due to death. Through the hypothetical strategy, we impute missing endpoint assessments with the assumption that participants are alive at this time. For both cases, the estimand formula is still $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C)$, and the meaning of the estimand is not changed.

This strategy estimates the pure effect of the experimental treatment. When the pure treatment effect is of major clinical importance in real world, this strategy would be appropriate.

3.3 The composite variable strategy

The composite variable strategy is to include intercurrent events in the endpoint definition. In case (2), suppose the endpoint is a disability index measured by questionnaires and it does not consider death. Since participants from case (2) die by the second assessment, the questionnaire measurement is not done at the second assessment. However, death indicates no physical function. Through the composite variable strategy, death is included in the worst disability category and thus can be used in data analysis. The estimand formula is still $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C)$, but now the definition of Y has been changed from disability measurement with no death included to disability measurement with death included in the worst disability category.

This strategy estimates the pure effect of the experimental treatment on a different endpoint. When composite endpoints are realistic in real world, this strategy would be appropriate.

3.4 The while on treatment strategy

The while on treatment strategy is to use available endpoints measured before intercurrent events and discard any data afterwards. In case (3), participants survive the first assessment but the endpoint is not measured at the second assessment due to death. Through the while on treatment strategy, we use the first assessment on the endpoint and all data up to the first assessment when participants from case (3) are included in primary analysis. This means that, for participants with intercurrent events, we only use their data that are recorded during treatment before intercurrent events. The estimand formula is still $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C)$, but now the definition of Y has been changed from measurement at the second assessment to measurement at the first or second assessment.

This strategy also estimates the pure effect of the experimental treatment on a different endpoint. When time is well adjusted in the endpoint definition, such as multiple-fixed-time endpoints as in this example and time-to-event endpoints, this strategy would be appropriate, otherwise we may have to explicitly adjust for time in statistical models.

3.5 The principal stratum strategy

The principal stratum strategy is to identify a subpopulation of participants who would or would not experience intercurrent events and estimate the ATE in this subpopulation instead of the entire target population.

In case (4), suppose we only want to know the treatment effect in the participants who would tolerate treatment toxicity. Tolerability of treatment toxicity is an intrinsic characteristic and should be interpreted from a hypothetical perspective. Suppose tolerability is represented by T. T=0 represents not tolerating treatment and T=1 represents tolerating treatment. Now, there are four subpopulations represented by P. P = 1 are participants who would tolerate both the control and experimental treatments if they took both treatments. P = 2 are participants who would tolerate neither the control treatment nor the experimental treatment if they took both treatments. P = 3 are participants who would tolerate the control treatment and would not tolerate the experimental treatment if they took both treatments. P = 4 are participants who would not tolerate the control treatment and would tolerate the experimental treatment if they took both treatments. And the subpopulation of participants who would tolerate both treatments, that is P = 1, becomes our new target population. These four subpopulations may not be directly observed in real world and may have to be estimated from real data. They are different from subgroups of participants who tolerate or do not tolerate treatment in real world. For example, there is a subgroup of participants in the control arm who tolerate the control treatment. From this subgroup, some participants might tolerate the experimental treatment if assigned to the treatment arm instead, while the others might not tolerate the experimental treatment if assigned to the treatment arm instead. Hence, this subgroup can be a mix of P = 1 and P = 3.

Potential outcomes should be modified to take T into account. For example, $Y_i(X_i(R_i = 0) = 0, T_i = 0)$ would be the outcome if the participant took but did not tolerate the control treatment. $Y_i(X_i(R_i = 1) = 1, T_i = 0)$ would be the outcome if the participant took but did not tolerate the experimental treatment. $Y_i(X_i(R_i = 0) = 0, T_i = 1)$ would be the outcome if the participant took and tolerated the control treatment. $Y_i(X_i(R_i = 1) = 1, T_i = 1)$ would be the outcome if the participant took and tolerated the experimental treatment. The estimand formula now becomes $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C, P = 1)$, with no changes in the definitions of X and Y.

This strategy estimates the pure treatment effect in a different target population. When specific subpopulations are of clinical interest, this strategy would be appropriate. Statistical methods with regard to this strategy may be complex, with more assumptions. Bayesian inference would be a good choice for this strategy.

3.6 Further possibilities

The above five strategies proposed in the estimand framework can be used in a flexible way. Several strategies can be used together. For example, the treatment policy strategy to analyze concomitant therapies is used with the principal stratum strategy to identify a subpopulation. A composite strategy that the treatment policy strategy to analyze allowed concomitant therapies is combined with the hypothetical strategy to analyze prohibited concomitant therapies has been proposed by industrial professionals [4].

In addition to the five strategies, there are also other strategies to analyze intercurrent events. For example, in case (1), suppose the dose of the control or experimental treatment has to be reduced after concomitant therapies are used and concomitant therapies affect the endpoint. We define a new variable M to represent concomitant therapies. M can be a binary variable that indicates whether concomitant therapies are used or not. It can also be the total dose or the dose frequency of concomitant therapies. Hence, M is a new confounder that affects both X and Y. And figure 3 is a causal directed acyclic graph that shows the causal relationships between X, Y, R, C, M.



Figure 3: Causal directed acyclic graph for X, Y, R, C, M.

The estimand formula now should be conditional on M as $E(Y_i(X_i(R_i = 1) = 1) - Y_i(X_i(R_i = 0) = 0) | C, M)$, but there is no change in the meaning of the estimand. Compared to the treatment policy strategy and the hypothetical strategy, this strategy of defining intercurrent events as confounders and using model adjustment does not modify the definitions of X, Y and the ATE, or modify any trial data. This strategy would be appropriate if the confounding effects of intercurrent events can be well adjusted for.

In practice, to create new strategies, more aspects should be considered, including efficiency, validity in various applications and suitability for regulatory activities. It would be recommended continuing developing new strategies for intercurrent events beyond the proposal of ICH E9(R1).

4 Target populations versus analysis sets

Analysis sets are a group of participants that meets specific criteria and is used for specific analytical objectives. ICH E9 proposed different analysis sets, including full analysis set (FAS) and per protocol set (PPS) [2]. There are also other analysis sets, including intention to treat set (ITTS) and safety set (SS). ITTS is usually all participants enrolled in study. SS comes from ITTS and is usually a group of participants who take treatment at least once. FAS comes from SS and excludes some participants whose data are not suitable for analysis, such as those who take no treatment after randomization. PPS comes from FAS and only includes participants whose data have no or little protocol deviation.

Different analysis sets can lead to different treatment effect estimates, because from the estimand framework, they are different target populations. In the estimand framework, analysis sets are actually not required. We can define analysis sets into target populations or use the principal stratum strategy to estimate treatment effects in subpopulations equal to analysis sets. However, analysis sets are usually subsets of all trial data. If we build statistical models through the estimand framework on data subsets, we may introduce selection bias and break randomization of the assignment scheme, which means that the participants in an analysis set may not be considered randomized any more. Without the randomization assumption, statistical inference on estimands may be unviable or biased. Hence, we should carefully examine randomization in analysis sets if they are used as target populations.

5 Conclusion

The estimator framework is advantageously useful for estimation of causal treatment effects. Learning and strengthening statistical causal inference theories behind the estimator framework would facilitate implementation and improvement of the estimator framework in industry.

Funding statement

There is no funding for this work.

References

- [1] D. B. Rubin, Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies, J Educ Psychol, Vol.66, pp.688-701, 1974, DOI: 10.1037/h0037350.
- [2] ICH Expert Working Group, *Statistical Principles for Clinical Trials E9*, 1998, https://www.ich.org/page/efficacy-guidelines#9-1.
- [3] ICH Expert Working Group, Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline of Statistical Principles for Clinical Trials E9 (R1), 2019, https: //www.ich.org/page/efficacy-guidelines#9-2.
- [4] J. Wei, Q. Du, W. Guo et al., *Blue Book of ICH E9 (R1) Estimands and Sensitivity Analysis*, DIA China Statistics Community, 2022.
- [5] P. W. Holland, Statistics and Causal Inference, J Am Stat Assoc, Vol.81, pp.945-960, 1986, DOI: 10.1080/01621459.1986.10478354.